Mutational analysis of candidate genes in Israeli male breast cancer cases

  • Hagit Schayek
  • Hila Korach
  • Yael Laitman
  • Rinat Bernstein-Molho
  • Eitan Friedman
Epidemiology

Abstract

Purpose

To define the mutational spectrum of several candidate gene mutations in Israeli male breast cancer cases.

Methods

MBC cases counselled at the Oncogenetics unit, Sheba Medical Center from January 1998 to June 2017 were included. Relevant clinical and oncological data and cancer phenotype were retrieved. All participants were genotyped for the predominant Jewish BRCA1 and BRCA2 germline mutations using a chip-based assay. Those who tested negative were further genotyped for three recurring mutations in CHEK2 (c.1100delC, p.S428F, p.I157T), and single mutations in the FANCM (c.5791C>T), and RAD51D (c.556C>T) genes, by direct sequencing. The ethics committee approved the study.

Results

Overall, 61 MBC were identified and genotyped, 41 (67.2%) were Ashkenazim, age at diagnosis was 58.1 ± 12.6 years, and 31 (50.8%) had a family history of cancer. Of genotyped individuals, one (1.6%) harboured the 185delAG* BRCA1 mutation, 7 (11.4%) the 6174delT*BRCA2 mutation and 2 (3.2%) other recurring mutations in BRCA2 (overall 10/61–16.4% BRCA1/BRCA2 mutation carriers). Of BRCA-negative cases, 3/51 (5.9%) carried the p.S428F *CHEK2 mutation. None was a carrier of the other genotyped mutations in CHEK2, FANCM or RAD51D.

Conclusion

BRCA1, BRCA2 and CHEK2 germline mutations contribute to inherited predisposition to MBC in Israel.

Keywords

Male breast cancer Inherited predisposition to cancer BRCA1 BRCA2 CHEK2 

Notes

Acknowledgements

This work was carried out in partial fulfilment for the degree of MD to Hila Korach, at the Sackler School of Medicine, Tel-Aviv University, Tel- Aviv, Israel. This study was in part funded by the Grant top the Israeli consortium of inherited breast and ovarian cancer.

Compliance with ethical standards

Conflict of interest

All authors confirm that they have no conflict of interest with the data reported herein.

References

  1. 1.
    Donegan WL, Redlich PN, Lang PJ, Gall MT (1998) Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83:498–509CrossRefPubMedGoogle Scholar
  2. 2.
    Ferzoco RM, Ruddy KJ (2016) The epidemiology of male breast cancer. Curr Oncol Rep 18(1):1–6CrossRefPubMedGoogle Scholar
  3. 3.
    Ottini L (2014) Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. Nat Rev Cancer 14(10):643.  https://doi.org/10.1038/nrc3806 CrossRefPubMedGoogle Scholar
  4. 4.
    Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A (1998) BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1361–1371Google Scholar
  5. 5.
    Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D (2012) Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat 134(1):411–418.  https://doi.org/10.1007/s10549-012-2062-0 CrossRefPubMedGoogle Scholar
  6. 6.
    Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161(3):575–586.  https://doi.org/10.1007/s10549-016-4085-4 CrossRefPubMedGoogle Scholar
  7. 7.
    Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:1888–1890CrossRefGoogle Scholar
  8. 8.
    Scheuer L, Robson M, Hamper H, Borgen P, Norton L, McDermott D, Pinto M, Hull J, Baum R, Nafa K, Ellis N, Schluger A, Offitt K (1999) Frequency of BRCA mutations among a series of Ashkenazi Jewish men diagnosed with breast cancer. Am J Hum Genet 65(Suppl):1805Google Scholar
  9. 9.
    Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J (1999) Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 65:1800–1802CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sverdlov RS, Barshack I, Bar Sade RB, Baruch RG, Hirsh-Yehezkel G, Dagan E, Feinmesser M, Figer A, Friedman E (2000) Genetic analyses of male breast cancer in Israel. Genet Test 4(3):313–317CrossRefPubMedGoogle Scholar
  11. 11.
    Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall’Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS., Mitchell G, James PA, Thompson E; kConFab.; SWE-BRCA., Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P (2015) FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum Mol Genet 24(18):5345–5355.  https://doi.org/10.1093/hmg/ddv251
  12. 12.
    Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L (2017) A possible role of FANCM mutations in male breast cancer susceptibility: results from a multicenter study in Italy. Breast 38:92–97.  https://doi.org/10.1016/j.breast.2017.12.013 CrossRefGoogle Scholar
  13. 13.
    Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59CrossRefGoogle Scholar
  14. 14.
    Sodha N, Wilson C, Bullock SL, Phillimore H, Houlston RS, Eeles RA (2004) Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215(2):187–189CrossRefPubMedGoogle Scholar
  15. 15.
    Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M (2009) CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 116(2):397–400.  https://doi.org/10.1007/s10549-008-0162-7 CrossRefPubMedGoogle Scholar
  16. 16.
    Hallamies S, Pelttari LM, Poikonen-Saksela P, Jekunen A, Jukkola-Vuorinen A, Auvinen P, Blomqvist C, Aittomäki K, Mattson J, Nevanlinna H (2017) CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer 17(1):620–624.  https://doi.org/10.1186/s12885-017-3631-8 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Syrjäkoski K, Kuukasjärvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108(3):475–476CrossRefPubMedGoogle Scholar
  18. 18.
    Evans DG, Bulman M, Young K, Howard E, Bayliss S, Wallace A, Lalloo F (2008) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7(2):113–1137CrossRefPubMedGoogle Scholar
  19. 19.
    Apostolou P, Fostira F, Papamentzelopoulou M, Michelli M, Panopoulos C, Fountzilas G, Konstantopoulou I, Voutsinas GE, Yannoukakos D (2015) CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. Cancer Genet 208(4):129–134.  https://doi.org/10.1016/j.cancergen.2015.02.006
  20. 20.
    Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108(3):479–480CrossRefPubMedGoogle Scholar
  21. 21.
    Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, King MC (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14(4):555–563CrossRefPubMedGoogle Scholar
  22. 22.
    Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110(1):161–167CrossRefPubMedGoogle Scholar
  23. 23.
    Byers H, Wallis Y, van Veen EM, Lalloo F, Reay K, Smith P, Wallace AJ, Bowers N, Newman WG, Evans DG (2016) Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing. Eur J Hum Genet 24(11):1591–1597.  https://doi.org/10.1038/ejhg.2016.57 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA (2017) Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS ONE 12(6):e0178450.  https://doi.org/10.1371/journal.pone.0178450 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, da Silva Filho AL, Friedman E (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte. Brazil Cancer Genet 209(1–2):50–52.  https://doi.org/10.1016/j.cancergen.2015.11.003 CrossRefPubMedGoogle Scholar
  26. 26.
    Mavraki E, Gray IC, Bishop DT, Spurr NK (1997) Germline BRCA2 mutations in men with breast cancer. Br J Cancer 76:1428–1431CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B, Olah E (1999) High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995–998PubMedGoogle Scholar
  28. 28.
    Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13(1):117–119CrossRefPubMedGoogle Scholar
  29. 29.
    Syrjäkoski K, Kuukasjärvi T, Waltering K, Haraldsson K, Auvinen A, Borg A, Kainu T, Kallioniemi OP, Koivisto PA (2004) BRCA2 mutations in 154 finnish male breast cancer patients. Neoplasia 6(5):541–545CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC (2017) Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish Women. JAMA Oncol 3(12):1647–1653.  https://doi.org/10.1001/jamaoncol.2017 CrossRefPubMedGoogle Scholar
  31. 31.
    Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26(4):542–548.  https://doi.org/10.1200/JCO.2007.12.5922 CrossRefPubMedGoogle Scholar
  32. 32.
    Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E (2007) Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr Med Assoc J. 9(11):791–796PubMedGoogle Scholar
  33. 33.
    Bar-Sade RB, Theodor L, Gak E, Kruglikova A, Hirsch-Yechezkel G, Modan B, Kuperstein G, Seligsohn U, Rechavi G, Friedman E (1997) Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Genet 5(6):413–416PubMedGoogle Scholar
  34. 34.
    Shtoyerman-Chen R, Friedman E, Figer A, Carmel M, Patael Y, Rath P, Fidder HH, Bar-Meir S, Theodor L (2001) The I1307 K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect. Genet Test 5(2):141–146CrossRefPubMedGoogle Scholar
  35. 35.
    Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans G, Latif A, Newman WG, Gershoni-Baruch R, Zidan J, Shimon-Paluch S, Goldgar D, Friedman E (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21(2):212–216.  https://doi.org/10.1038/ejhg.2012.124 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Susanne Levy Gertner Oncogenetics UnitInstitute of Human Genetics, Sheba Medical CenterTel-HahsomerIsrael
  2. 2.The Breast Cancer Unit, Oncology InstituteSheba Medical CenterTel-HashomerIsrael
  3. 3.The Sackler School of MedicineTel-Aviv UniversityTel-AvivIsrael
  4. 4.The Danek Gertner Institute of Human GeneticsChaim Sheba Medical CenterTel-HashomerIsrael

Personalised recommendations